Blockchain Registration Transaction Record

Late-Stage Biopharmaceutical Company Clene (NASDAQ: CLNN) Enters Securities Purchase Agreement

Clene Inc., a late clinical-stage biopharmaceutical company, has entered into a securities purchase agreement, issuing 742,626 shares of common stock for an estimated $7.3 million. The company is focused on developing therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

This news is important because it highlights a significant financial transaction for Clene Inc., a company dedicated to developing innovative therapies for neurodegenerative diseases. The agreement will provide the company with substantial gross proceeds, furthering its mission of improving mitochondrial health and protecting neuronal function.